Articles related to ALZHEIMER'S/DEMENTIA

The update, which was presented during a panel discussion at the Alzheimer Association International Conference 2022 (AAIC2022) in San Diego, CA, is based on evidence from real-world use of aducanumab and is intended to improve risk mitigation, safety monitoring, patient selection, and shared decision-making.

The first in a two-part series, this 0.50-credit, 30-minute CME multiplatform program discusses the importance of early identification of AD and how to detect it early, the pathobiology of AD and potential treatments in development to target this pathology, and current treatment options, including the appropriate use of anti-amyloid monoclonal antibody (mAb) treatment.

As this review discovered, repurposing of established noradrenergic drugs is most likely to offer effective treatment in Alzheimer’s disease for general cognition and apathy. Still, the report offers several factors that should be considered before designing future clinical trials.

The Lumipulse G β-Amyloid Ratio (1-42/1-40) test could potentially eliminate the need for positron emission tomography (PET) scans to assess amyloid plaques in patients’ brains, Jeff Shuren, MD, JD, director of the FDA’s Center for Devices and Radiological Health, said in a statement.

A fact-filled video program all about ALZ-801 (valiltramiprosate), an oral medication with a novel mode of action that aims to slow or stop Alzheimer’s disease altogether.

Data for this study came from Danish medical registries over a 20-year period for 247,305 people who visited a hospital or were prescribed antiviral medication for herpes zoster and 1,235,890 people who did not have the disease. These individuals were an average age 64. Up to 21 years later, 9.7% of those with vs. 10.3% of those without herpes zoster developed dementia.